Status:
ACTIVE_NOT_RECRUITING
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
Lead Sponsor:
Vanda Pharmaceuticals
Conditions:
Motion Sickness
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
Detailed Description
This is an open label study to investigate the efficacy and safety of tradipitant in motion sickness affected male and female participants during events historically known to cause motion sickness.
Eligibility Criteria
Inclusion
- History of Motion Sickness
- Age 18-75
Exclusion
- Nausea-inducing disorder other than motion sickness
- BMI \> 40
- History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists
Key Trial Info
Start Date :
February 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2026
Estimated Enrollment :
705 Patients enrolled
Trial Details
Trial ID
NCT06138613
Start Date
February 27 2023
End Date
June 30 2026
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Santa Monica Clinical Trials
Santa Monica, California, United States, 90404